Skip to main content

Table 1 Point estimates for incidence of unspecified dose adjustment, dose increase and dose decrease for individual studies included in the systematic review

From: Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007–2017)

Study Study arma Unspecified dose adjustment (direction not specified), point estimate (%) for incidence (95% CI) Dose increase, point estimate (%) for incidence (95% CI) Dose decrease, point estimate (%) for incidence (95% CI)
Allegra 2017 [48] Control (N = 99) 72.7 (64.0, 81.5)
Nomogramb (N = 92) 60.9 (50.9, 70.8)
Buhler 2014 [49] (N = 2074) 4.8 (3.9, 5.7) 3.7 (2.9, 4.5)
Magnusson 2017 [58] AMH (N = 152) 54.6 (46.7, 62.5)
Non-AMH (N = 155) 52.3 (44.4, 60.1)
Espinós 2017c [52] (N = 41) 26.8 (13.3, 40.4)
Nyboe Andersen 2017 [9] r-hFSH (N = 661) 36.8 (33.1, 40.4)
Rettenbacher 2015 [62] Bemfola (N = 220) 17.3 (12.3, 22.3)
GONAL-f (N = 113) 14.2 (7.7, 20.6)
Strowitzki 2016 [63] Ovaleap (N = 153) 35.9 (28.3, 43.6) 15.0 (9.4, 20.7)
GONAL-f (N = 146) 43.2 (35.1, 51.2) 15.1 (9.3, 20.9)
Devroey 2012 [50] r-hFSH (N = 375)   24.8 (20.4, 29.2) 2.1 (0.7, 3.6)
Durnerin 2008 [51] Control (N = 49) 55.1 (41.2, 69.0) 2.0 (−1.9, 6.0)
r-hLH pretreat (N = 53) 54.7 (41.3, 68.1) 3.8 (−1.4, 8.9)
Esteves 2009 [53] r-hFSH (N = 236) 53.4 (47.0, 59.8)
Devroey 2009 [54] r-hFSH (N = 750) 8.4 (6.4, 10.4%)
Freiesleben 2008 [55] r-hFSH (N = 159) 44.0 (36.3, 51.7)
Kyrou 2009 [56] r-hFSH (N = 230) 3.0 (0.8, 5.3) 7.0 (3.7, 10.2)
Lossl 2008 [57] Androgen priming (N = 53) 58.5 (45.2, 71.8) 1.9 (−1.8, 5.5)
Control (N = 50) 52.0 (38.2, 65.8) 2.0 (−1.9, 5.9)
Nakhuda 2010d [59] (N = 104) 10.6 (4.7, 16.5) 35.6 (26.4, 44.8)
Nyboe Andersen 2008 [60] r-hFSH (N = 261) 51.7 (45.7, 57.8) 11.5 (7.6, 15.4)
r-hFSH + r-hLH (N = 265) 48.7 (42.7, 54.7) 11.3 (7.5, 15.1)
Requena 2010 [61] r-hFSH + HP-hMG (N = 46) 32.6 (19.1, 46.2)
r-hFSH (N = 46) 32.6 (19.1, 46.2)
Yovich 2012 [40] FSH dose < 100 IU (N = 47) 53.2 (38.9, 67.5)
  1. AMH anti-Müllerian hormone, FSH follicle stimulating hormone, r-hFSH recombinant-human follicle stimulating hormone, r-hLH recombinant-human luteinizing hormone, HP-hMG highly purified human menopausal gonadotropin
  2. aOnly study arms using recombinant FSH were included in the data analysis; bFSH starting dose set using a nomogram based on age, serum Day 3 FSH and AMH; cStudy in obese women; dStudy in oocyte donors